Valneva SE (XPAR:VLA) Share Price

Company Profile

Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRA
T: +33 228073710
E: [email protected]
https://www.valneva.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.50	34.00	-0.37%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,548.27	109.76	0.42%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,652.08	749.81	1.67%
NZX 50 Index	13,222.12	12.77	-0.10%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,800.00	48.50	-0.55%
SSE Composite Index	3,822.12	9.54	-0.25%